ACE and chronic kidney disease: As such, the treatment algorithm from JNC-VIII guidelines suggested the use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) for hypertensive patients with CKD for all races, thiazides or calcium channel blockers (CCB) for black, non-CKD hypertensive patients, and ACE/ARB, thiazides, or CCB for non-black, non-CKD hypertensive patients (Figure 1) [3].